近3年最强流感季来袭：部分药店特效药缺货，儿童“一次口服”流感药还会紧俏多久？

Core Viewpoint - The flu season of 2025 is reported to be more severe than in the past three years, with increased cases of flu-like illnesses (ILI) across both northern and southern regions of China, leading to a shortage of specific flu medications, particularly for children [1][3][11]. Summary by Sections Flu Season Severity - The latest report from the Chinese Center for Disease Control and Prevention indicates that from November 10 to 16, 2025, the ILI percentage in southern provinces was 6.7% and in northern provinces was 7.0%, both higher than the previous week and the same period in 2022, 2023, and 2024 [3][11]. Medication Shortages - Many pharmacies are experiencing shortages of flu medications, particularly the children's version of the antiviral drug "速福达" (Mabalaoshuwei). Traditional antiviral drugs like Oseltamivir are still available but are also in high demand [3][9][11]. - A pharmacy reported that Oseltamivir has been out of stock for over two weeks, with expectations for new supplies to arrive soon, while "速福达" is not expected to be restocked [9][11]. Hospital Preference - Parents prefer hospitals for flu treatment over pharmacies, as they trust clinical doctors more. The original manufacturers of "速福达" and Oseltamivir are ensuring a broad supply to hospitals across the country [10][11]. - Clinical demand for children's flu medications is increasing, with doctors noting that while there are no supply issues for Oseltamivir and Mabalaoshuwei, delivery disruptions can occur due to high demand [11][12]. Drug Efficacy and Usage - Oseltamivir is suitable for children aged 1 year and older, while Mabalaoshuwei is effective for children aged 5 to 12, with the latter being a single-dose oral medication, making it more convenient for parents [11][13]. - The latest guidelines indicate that flu medications are essential for treatment, as common cold medications do not replace antiviral drugs [12][13]. Market Dynamics - The market for children's single-dose flu medications is expected to become more competitive as several domestic pharmaceutical companies are developing similar products, which may challenge the current dominance of "速福达" [16][17]. - Recent approvals for new antiviral drugs targeting children are underway, with a focus on single-dose formulations, which could expand treatment options for pediatric patients [16][17].